Eloralintide for knee osteoarthritis pain in adults who are overweight or have obesity
Tests eloralintide against placebo in adults with painful knee osteoarthritis and excess weight.
Plain-language title generated from the registry record
Registry title: Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
Key facts
- Where
- Beijing, Bengbu, Changchun, Changsha, Chongqing, Hangzhou, Hefei, Jinan, Luoyang, Nanjing, Ningbo, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan, and Xianyang, ChinaSee the 23 sites
- Phase
- Phase 3
Where in China
- Beijing Ji Shui Tan HospitalBeijing, ChinaTaking people
- The First Afflilated Hospital of Bengbu Medical CollegeBengbu, ChinaTaking people
- Jilin Province People's HospitalChangchun, ChinaTaking people
- The Second Hospital of Jilin UniversityChangchun, ChinaTaking people
- Xiangya Hospital Central South UniversityChangsha, ChinaTaking people
- 2nd Affiliated Hospital Chongqing Medical UniversiChongqing, ChinaTaking people
- The Second Affiliated Hospital of Zhejiang University School of MedicineHangzhou, ChinaTaking people
- The Second People's Hospital of HefeiHefei, ChinaTaking people
- Jinan Central HospitalJinan, ChinaTaking people
- The First Affiliated Hospital of Henan University of Science &TechnologyLuoyang, ChinaTaking people
- Jiangsu Province HospitalNanjing, ChinaTaking people
- Nanjing First HospitalNanjing, ChinaTaking people
- The Second Affiliated Hospital of Nanjing Medical UniversityNanjing, ChinaTaking people
- Zhongda Hospital Southeast UniversityNanjing, ChinaTaking people
- The First Affiliated Hospital of Ningbo UniversityNingbo, ChinaTaking people
- Huashan Hospital, Fudan UniversityShanghai, ChinaTaking people
- Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of MedicineShanghai, ChinaTaking people
- Zhongshan Hospital,Fudan UniversityShanghai, ChinaTaking people
- The Second Affiliated Hospital of Soochow UniversitySuzhou, ChinaTaking people
- Tianjin HospitalTianjin, ChinaTaking people
- The 2nd Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical UniversityWenzhou, ChinaTaking people
- Tongji Hospital Tongji Medical,Science & TechnologyWuhan, ChinaTaking people
- Xianyang Hospital of Yan'an UniversityXianyang, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07353931EU 2025-523768-19-00
- Record updated
- 4 November 2026
- Original description
The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening.Read full original descriptionShow less
A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Osteoarthritis Knee Pain, and Obesity or Overweight (ENLIGHTEN-4)
The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening.
Inclusion: Have a body mass index (BMI) of 27 kilograms per square meter (kg/m²) or higher at screening; Have a stable body weight (less than 5% body weight change) for 90 days prior to screening; Have tried at least once to lose weight through diet but were unsuccessful; Have osteoarthritis of the knee and at least one of the following conditions:; Be over 50 years old; Have morning knee stiffness that lasts about 30 minutes; Have a crackling or grinding sound or feeling in the knee.
Exclusion: Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed greater than 1 year before screening); Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening); Have had within 90 days prior to screening:; heart attack; stroke; coronary artery revascularization; unstable angina, or; hospitalization due to congestive heart failure; Have taken medications or alternative remedies intended for weight loss within 90 days of screening; Have type 1 diabetes, type 2 diabetes, or any other type of diabetes; Have an active knee infection; Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure.